51
|
Gressens P, Arquié C, Hill JM, Marret S, Sahir N, Robberecht P, Evrard P. VIP and PACAP 38 modulate ibotenate-induced neuronal heterotopias in the newborn hamster neocortex. J Neuropathol Exp Neurol 2000; 59:1051-62. [PMID: 11138925 DOI: 10.1093/jnen/59.12.1051] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Intracerebral administration of ibotenate produces, through activation of N-methyl-D-aspartate (NMDA) receptors, neuronal heterotopias in the newborn hamster neocortex: high doses of ibotenate induce periventricular and subcortical neuronal heterotopias, while low doses of ibotenate produce intracortical heterotopias and molecular layer ectopias. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) are closely related peptides with neurotrophic properties. They share common VPAC1 and VPAC2 receptors, which use cAMP as a second messenger. Previous studies have shown that VIP prevents excitotoxic neuronal death and exacerbates glutamate-induced c-fos neuronal expression. In order to gain new insight into the molecular control of neuronal migration, the present study examined the effects of VIP and PACAP on ibotenate-induced heterotopias in the newborn hamster. Co-treatment with VIP and a high dose of ibotenate produced a pattern of neuronal heterotopias similar to the one observed in animals treated with low doses of ibotenate alone. Pups co-injected with a low dose of ibotenate and a VIP antagonist displayed cortical dysgeneses similar to those observed in animals treated with high doses of ibotenate alone. The modulating effects of VIP on excitotoxin-induced heterotopias were mimicked by forskolin, PACAP, and by a specific VPAC2 receptor agonist but not by a VPAC1 agonist, and were blocked by a protein kinase A (PKA) inhibitor. Taken together, these data suggest that VIP and PACAP can attenuate ibotenate-induced heterotopias in newborn hamster and that this effect is mediated by the VPAC2 receptor utilizing the cAMP-PKA pathway.
Collapse
Affiliation(s)
- P Gressens
- INSERM E 9935, H pital Robert-Debré, Paris, France
| | | | | | | | | | | | | |
Collapse
|
52
|
Blondel O, Collin C, McCarran WJ, Zhu S, Zamostiano R, Gozes I, Brenneman DE, McKay RD. A glia-derived signal regulating neuronal differentiation. J Neurosci 2000; 20:8012-20. [PMID: 11050122 PMCID: PMC6772724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023] Open
Abstract
Astrocytes are present in large numbers in the nervous system, are associated with synapses, and propagate ionic signals. Astrocytes influence neuronal physiology by responding to and releasing neurotransmitters, but the mechanisms that establish the close interaction between these cells are not defined. Here we use hippocampal neurons in culture to demonstrate that vasoactive intestinal polypeptide (VIP) promotes neuronal differentiation through activity-dependent neurotrophic factor (ADNF), a protein secreted by VIP-stimulated astroglia. ADNF is produced by glial cells and acts directly on neurons to promote glutamate responses and morphological development. ADNF causes secretion of neurotrophin 3 (NT-3), and both proteins regulate NMDA receptor subunit 2A (NR2A) and NR2B. These data suggest that the VIP-ADNF-NT-3 neuronal-glial pathway regulates glutamate responses from an early stage in the synaptic development of excitatory neurons and may also contribute to the known effects of VIP on learning and behavior in the adult nervous system.
Collapse
Affiliation(s)
- O Blondel
- Laboratory of Molecular Biology, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
| | | | | | | | | | | | | | | |
Collapse
|
53
|
Sahir N, Bahi N, Evrard P, Gressens P. Caffeine induces in vivo premature appearance of telencephalic vesicles. BRAIN RESEARCH. DEVELOPMENTAL BRAIN RESEARCH 2000; 121:213-7. [PMID: 10876034 DOI: 10.1016/s0165-3806(00)00037-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Caffeine administered to pregnant mice during germinative neuroepithelium preparation (embryonic days 8-10) dramatically accelerated primitive neuroepithelium evagination into telencephalic vesicles, versus age-matched controls. This histologically-documented, dose-dependent effect seemed reversible during subsequent neuronal migration if caffeine exposure was discontinued. Our in vivo model provides a new tool for studying telencephalic symmetry acquisition and for identifying genes potentially involved in holoprosencephaly, a developmental disorder characterized by defective telencephalic vesicle formation.
Collapse
Affiliation(s)
- N Sahir
- Service de Neurologie Pédiatrique, Hôpital Robert-Debré, 48 Blvd. Sérurier, 75019, Paris, France
| | | | | | | |
Collapse
|
54
|
Hill JM, Glazner GW, Lee SJ, Gozes I, Gressens P, Brenneman DE. Vasoactive intestinal peptide regulates embryonic growth through the action of activity-dependent neurotrophic factor. Ann N Y Acad Sci 2000; 897:92-100. [PMID: 10676438 DOI: 10.1111/j.1749-6632.1999.tb07881.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Activity-dependent neurotrophic factor is a potent, neuroprotective protein released from astroglia by VIP and accounts in part for the neuroprotective properties of this neuropeptide. The growth-regulatory actions of VIP during embryogenesis may also occur indirectly through the release of activity-dependent neurotrophic factor. Whole cultured day-9 mouse embryos treated with activity-dependent neurotrophic factor (10(-13) M) for 4 hr grew 3.1 somites, compared with 1.6 somites in control embryos. Treated embryos appeared morphologically normal and exhibited significant increases in cross-sectional area, protein, and DNA content and bromodeoxyuridine incorporation. Anti-activity-dependent neurotrophic factor significantly inhibited growth. Co-treatment of embryos with anti-activity-dependent neurotrophic factor inhibited VIP-stimulated growth; however, anti-VIP did not inhibit activity-dependent neurotrophic factor-induced growth. These data indicate that an activity-dependent neurotrophic factor-like substance is an endogenous embryonic growth factor and that VIP-regulated growth occurs, at least in part, through activity-dependent neurotrophic factor.
Collapse
Affiliation(s)
- J M Hill
- Section on Developmental and Molecular Pharmacology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA.
| | | | | | | | | | | |
Collapse
|
55
|
Spong CY, Lee SJ, McCune SK, Gibney G, Abebe DT, Brenneman DE, Hill JM. Regulation of postimplantation mouse embryonic growth by maternal vasoactive intestinal peptide. Ann N Y Acad Sci 2000; 897:101-8. [PMID: 10676439 DOI: 10.1111/j.1749-6632.1999.tb07882.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Vasoactive intestinal peptide (VIP) is an identified regulator of growth in the embryonic day (E) 9-11 mouse. Mouse embryonic and extra-embryonic tissues were studied to identify the source of VIP at this critical time. VIP and mRNA was detected in the decidua/trophoblast at E8 and declined until E10, after which it was not detectable. VIP mRNA was not apparent in the embryo until E11-E12. At E9, cells in decidua had VIP as well as lymphocyte marker (delta and CD3) immunoreactivity. VIP binding sites were dense in the decidua/trophoblast at E6, which gradually decreased until E10. VIP binding sites were detected in embryonic neuroepithelium by E9. The transient presence of VIP binding sites and mRNA in the decidua/trophoblast correlate with the identified period of VIP growth regulation, when VIP mRNA is absent in the embryo. Therefore, these findings suggest that maternal decidual lymphocytes are the source of VIP that regulate early postimplantation embryonic growth.
Collapse
Affiliation(s)
- C Y Spong
- Section on Developmental and Molecular Pharmacology, NICHD, NIH, Bethesda, Maryland 20892, USA
| | | | | | | | | | | | | |
Collapse
|
56
|
Abstract
Intracerebral administration of the excitotoxin ibotenate to new-born mice induced white-matter lesions mimicking the periventricular leukomalacia occurring in human premature babies. In this model, co-injection of vasoactive intestinal peptide (VIP) prevented white-matter lesions. VIP did not prevent the initial appearance of white-matter lesion, but promoted a secondary repair with axonal regrowth. Co-administration of ibotenate, VIP, and transduction inhibitors showed that protein kinase C (PKC) and mitogen-associated protein kinase (MAPK) pathways were critical for neuroprotection. The combination of in vitro and in vivo studies suggested the following model: VIP activates PKC in astrocytes, which release soluble factors; these released factors activate neuronal MAPK and PKC, which will permit axonal regrowth. Previous studies had shown that VIP-treated cultured astrocytes release growth factors including activity-dependent neurotrophic factor (ADNF) and that a 14-amino-acid peptide derived from ADNF protected the developing white matter against ibotenate. However, co-treatment with ibotenate, VIP, and anti-ADNF antibodies did not abolish VIP-induced protection, suggesting that ADNF does not mediate VIP protective properties in the present model.
Collapse
Affiliation(s)
- P Gressens
- Service de Neuropédiatrie and INSERM E 9935, Hôpital Robert-Debré, Paris, France.
| |
Collapse
|
57
|
Zupan V, Nehlig A, Evrard P, Gressens P. Prenatal blockade of vasoactive intestinal peptide alters cell death and synaptic equipment in the murine neocortex. Pediatr Res 2000; 47:53-63. [PMID: 10625083 DOI: 10.1203/00006450-200001000-00012] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Vasoactive intestinal peptide (VIP) is a potent growth factor that stimulates murine neocortical astrocyte genesis during the period of ontogenesis corresponding to premature delivery in humans. In rodents, part of the VIP supplied to the fetal brain is maternal VIP that crosses the placenta. If these data also apply to human brain development, premature newborns may be partly VIP-deficient because of loss of the maternal supply, and this may adversely affect their brain development. The goal of the present study was to determine the effects of VIP blockade during mouse neocortical astrocyte genesis on neuritic survival and maturation. VIP blockade by a specific VIP antagonist on embryonic d 17 and 18 induced transient, postnatal depletion of astrocytes in the upper neocortical layers. Combined use of in situ DNA fragmentation analysis (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling method, a marker of cell death); immunohistochemical detection of synaptophysin, microtubule-associated proteins, and neurofilaments; and quantification of mRNA for synaptophysin and N-methyl-D-aspartate R1 receptor subunit revealed that early VIP blockade significantly altered programmed neuritic death and impaired neuritic differentiation. VIP inhibition induced 1) exaggerated postnatal terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling of cortical neurons, 2) long-term overexpression of synaptophysin and N-methyl-D-aspartate R1 receptor subunit, and 3) long-term overexpression of microtubule-associated protein-5 and neurofilament 160 kD. Although the functional consequences of this deviant pattern of murine neocortical development remain to be determined, these data open up new avenues for investigating some of the cognitive deficits observed in human premature infants.
Collapse
Affiliation(s)
- V Zupan
- INSERM E 9935, Hôpital Robert-Debré, Paris, France
| | | | | | | |
Collapse
|
58
|
Mathieu M, Trabucchi M, Vallarino M, Pinelli C, Rastogi RK. Distribution of vasoactive intestinal peptide-like immunoreactivity in the brain and pituitary of the frog (Rana esculenta) during development. Brain Res 1999; 851:105-15. [PMID: 10642833 DOI: 10.1016/s0006-8993(99)02130-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The localization of vasoactive intestinal peptide (VIP)-like immunoreactive (ir) elements was investigated in the brain of the anuran amphibian, Rana esculenta, during development. Using an antiserum raised against the porcine VIP, ir cell bodies and fibers were observed in the forebrain of tadpoles a few days after hatching. During early premetamorphosis, ir perikarya were distributed in the ventral infundibular nucleus of the hypothalamus and in the posterocentral nucleus of the thalamus. Labeled fibers were detected in the olfactory bulbs and in the hypothalamus. In these larvae, furthermore, several VIP-ir cells were found in the pars distalis of the pituitary and there were ir fibers in the pars nervosa. In tadpoles at stages VIII-IX, a new group of VIP-labeled neurons was observed in the dorsal part of the infundibular nucleus. In other brain regions, the distribution of the immunoreactivity was similar to that described in the earliest stages, i.e., IV-VII. During mid-premetamorphosis, stages X-XII of development, an additional set of ir perikarya appeared in the ventrolateral area of the thalamus. During late premetamorphosis, stages XIII-XVIII, the organization of VIP-like immunoreactivity was more complex and its distribution more widespread. Two new groups of ir cell bodies appeared, one in the preoptic nucleus and another in the anteroventral area of the thalamus, and for the first time, VIP immunoreactivity was observed in the median eminence. This distribution pattern persisted through to the prometamorphic, four-limb stage. Strikingly, no VIP-ir elements were observed anywhere in the mid- and hindbrain. The present results indicate that a VIP-like ir peptide may be involved in the processing of olfactory information or may act as a neurohormone, hypophysiotropic factor, and neuromodulator in the brain of R. esculenta during development.
Collapse
Affiliation(s)
- M Mathieu
- Dipartimento di Biologia Sperimentale, Università di Genova, Italy
| | | | | | | | | |
Collapse
|
59
|
Abstract
Neuropathic pain arising from direct trauma to, or compression injury of, peripheral nerves is a common clinical problem. It is characterized by the development of abnormal pain states (spontaneous pain, hyperalgesia, allodynia), which can persist long after the initial injury has resolved. The underlying mechanisms are poorly understood and, as a consequence, treatment is often unsatisfactory. Some of the main contributing factors are thought to be the morphological and phenotypic changes that occur centrally, including alterations in the expression of neurotransmitters and their associated receptors, both in the dorsal root ganglia and in the spinal dorsal horn. This article focuses on the functional role of the two structurally related peptides VIP and PACAP within the spinal cord, and their possible contribution to the altered transmission of sensory information in neuropathic conditions.
Collapse
Affiliation(s)
- T Dickinson
- Department of Pharmacology, Quintiles Scotland Ltd, Research Avenue South, Heriot-Watt University Research Park, Riccarton, Edinburgh, UK EH14 4AP
| | | |
Collapse
|
60
|
Spong CY, Lee SJ, McCune SK, Gibney G, Abebe DT, Alvero R, Brenneman DE, Hill JM. Maternal regulation of embryonic growth: the role of vasoactive intestinal peptide. Endocrinology 1999; 140:917-24. [PMID: 9927324 DOI: 10.1210/endo.140.2.6481] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Vasoactive intestinal peptide (VIP) is an important growth regulator of the embryonic day (E)9-E11 mouse. In comparably aged rat embryos, VIP messenger RNA (mRNA) is not detectable; however, peak concentrations of VIP in maternal rat serum indicate a nonembryonic source. In the current study, mouse maternal and embryonic tissues were examined from E6-E12. Although RT-PCR revealed VIP mRNA in E6-E7 conceptuses, by E8 (when extraembryonic tissues could be separated from the embryo), VIP mRNA was detected only in the decidua/trophoblast. Decidual/trophoblastic VIP mRNA decreased until E10, after which it was not detectable. VIP mRNA was not apparent in the embryo until E11-E12. At E9, VIP immunoreactivity was localized to abundant, diffuse cells in the decidua basalis, which were also immunoreactive for T cell markers. VIP binding sites were dense in the decidua/trophoblast at E6, but gradually decreased until E10, after which they were not apparent. VIP binding sites were detected in embryonic neuroepithelium by E9. The transient presence of VIP binding sites and mRNA in the decidua/trophoblast correlate with the critical period of VIP growth regulation, when VIP mRNA is absent in the embryo. These findings suggest that maternal lymphocytes are the source of VIP's regulating early postimplantation embryonic growth.
Collapse
Affiliation(s)
- C Y Spong
- Section on Developmental and Molecular Pharmacology, Laboratory of Developmental Neurobiology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA
| | | | | | | | | | | | | | | |
Collapse
|
61
|
Lamboley G, Evrard P, Gressens P. [Prenatal inhibition of intestinal vasoactive peptide and cerebral excitatory lesions in the newborn mouse]. Arch Pediatr 1999; 6:67-74. [PMID: 9974100 DOI: 10.1016/s0929-693x(99)80077-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The glutamatergic agent ibotenate induces cortical plate and white matter lesions in the newborn mouse, mimicking brain lesions of the human neonate. In this model, co-treatment with ibotenate and a vasoactive intestinal peptide antagonist (VA) aggravates the excitotoxic lesions, suggesting a protective role of endogenous VIP. On the other hand, prenatal injection of VA is followed by a dramatic depletion of astrocytes in the neocortex. Since astrocytes produce numerous neuronotrophic agents, we studied the consequences of a decreased astrocytic density by prenatal VIP blockade on the excitotoxic brain lesions in newborn mice. Pregnant females were pre-treated with VA during the last 2 days of gestation and ibotenate was intracerebrally injected on postnatal day (P) 2 or P5. When compared to controls, pups pre-treated with VA and injected with ibotenate at P2 displayed a significant reduction of the white matter lesion size while cortical plate lesion was not affected. This protective effect disappeared when ibotenate was injected at P5. White matter protection by VA pre-treatment did not seem to be linked to the decreased astrocytic density since, i) this astrocytic paucity concerns only superficial cortical layers and does not affect white matter, ii) protective effects are only observed at P2 while astrocytic density reduction is observed at P2 and P5. This white matter protection could be secondary to an up-regulation of VIP receptors: an increased density of VIP receptors, which was described in other developmental models following VA treatment, could increase the efficacy of the endogenous VIP after an excitotoxic insult.
Collapse
Affiliation(s)
- G Lamboley
- Service de neurologie pédiatrique, hôpital Robert-Debré, Paris, France
| | | | | |
Collapse
|
62
|
Gozes I, Perl O, Zamostiano R, Rubinraut S, Fridkin M, Shochat L, Lewin LM. Multiple actions of a hybrid PACAP antagonist: neuronal cell killing and inhibition of sperm motility. Ann N Y Acad Sci 1998; 865:266-73. [PMID: 9928021 DOI: 10.1111/j.1749-6632.1998.tb11187.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Pituitary stimulating adenylate cyclase (PACAP) is a major regulatory peptide with two active molecular forms: PACAP-27 and PACAP-38. Both molecular forms promote neuronal survival and protect against neurotoxicity. Based on our previous hybrid peptide strategy in designing vasoactive intestinal peptide (VIP) antagonists, novel PACAP analogues were synthesized (neurotensin6-11 PACAP7-27 and neurotensin6-11 PACAP7-38). In addition to the hybrid modification, the methionine in position 17 was replaced by norleucine (Nle). Treatment of rat cerebral cortical cultures for five days with the putative PACAP antagonists (1 nM) resulted in a 35-45% reduction in neuronal cell counts as compared to controls. Neuronal cell death was already obtained at picomolar concentrations for the neurotensin6-11 PACAP7-27 antagonist with 70% death at 10(-8) M. Co-administration of the PACAP hybrid analogue with picomolar amounts of PACAP-27 or Nle17-PACAP-27 attenuated the reduction in neuronal cell counts. While the protective effects of both analogues exhibited a peak at 1 pM concentrations, the Nle-containing agonist displayed a broader range of active concentrations (10(-12)M-10(-9) M). The putative PACAP antagonist also inhibited sperm motility (golden hamster) in a dose-dependent manner as assessed in vitro. Complete inhibition was observed at 10 microM, suggesting a role for PACAP in sperm motility and sexual function. Thus, previous findings of a large number of PACAP and PACAP receptors in the nervous system and the reproductive system are now correlated with a function in neuronal survival and sperm motility. The structure-activity studies suggest that the methionine in position 17 and the first six amino acids are important in the determination of PACAP activity, knowledge that may facilitate PACAP-based drug design.
Collapse
Affiliation(s)
- I Gozes
- Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Israel.
| | | | | | | | | | | | | |
Collapse
|
63
|
Sheward WJ, Lutz EM, Copp AJ, Harmar AJ. Expression of PACAP, and PACAP type 1 (PAC1) receptor mRNA during development of the mouse embryo. BRAIN RESEARCH. DEVELOPMENTAL BRAIN RESEARCH 1998; 109:245-53. [PMID: 9729410 DOI: 10.1016/s0165-3806(98)00086-8] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) have been reported to have a number of neurotrophic effects. We have examined the expression of mRNA for PACAP and PACAP type 1 (PAC1) receptor in the mouse embryo by in situ hybridization and the effects of PACAP and VIP on the growth of mouse embryos in vitro. Although we were unable to detect gross effects of either peptide on the growth rates of embryos maintained in culture, mRNAs for both PAC1 receptor and PACAP peptide were present in the nervous system from day 9.5 of embryonic development. PAC1 receptor mRNA was most abundant in the neural tube and the rhombencephalon and was present also in the dorsal root and trigeminal ganglia and the sympathetic chain. The distribution of mRNA for the PACAP peptide overlapped in part with that of the receptor, but was more extensively distributed in the rhombencephalon and in the developing hypothalamus. Within the neural tube, PAC1 receptor mRNA was located in the roof and floor plates, while the distribution of PACAP peptide mRNA was more complex, being located in two columns of cells in the ventromedial neural tube (consistent with the position of developing autonomic motor neurons) and in cells in the dorsolateral neural tube. These data are concordant with a role for PACAP or a related peptide in neural development.
Collapse
Affiliation(s)
- W J Sheward
- MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Morningside Park, Edinburgh, EH10 5HF, UK.
| | | | | | | |
Collapse
|
64
|
|
65
|
Abstract
Vasoactive intestinal peptide (VIP) is a 28-amino acid neuropeptide with potent growth-related actions on dissociated neural cells. In recent years its role in brain development has been elucidated: VIP has been shown to be a regulator of early neurodevelopment and embryonic growth, a stimulator of neocortical astrocytogenesis and a neuroprotective molecule against excitotoxic and other neurotoxic substances. Thus VIP appears as a fundamental regulator of brain growth and development, and a potent neuroprotective agent, possibly involved in pathological processes such as microcephalies and some neurological impairments observed in very premature babies. Similarly, VIP and VIP derivatives could represent a new avenue in the search of therapeutics for excitotoxic lesions of the developing brain.
Collapse
Affiliation(s)
- P Gressens
- Service de neurologie pédiatrique et Inserm CRI 97-01, Hôpital Robert-Debré, Paris, France
| |
Collapse
|
66
|
Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 1998; 50:265-70. [PMID: 9647867 PMCID: PMC6721840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Affiliation(s)
- A J Harmar
- MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Scotland, UK.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
67
|
Gressens P, Paindaveine B, Hill JM, Evrard P, Brenneman DE. Vasoactive intestinal peptide shortens both G1 and S phases of neural cell cycle in whole postimplantation cultured mouse embryos. Eur J Neurosci 1998; 10:1734-42. [PMID: 9751145 DOI: 10.1046/j.1460-9568.1998.00172.x] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Vasoactive intestinal peptide, a trophic and mitogenic factor, stimulates growth in whole cultured mouse embryos. Inhibition of this growth function between embryonic days 9 and 11 induces growth retardation accompanied by severe microcephaly. In the present study, to determine the effects of this peptide on the different phases of the cell cycle of neural cells, embryonic day 9.5 cultured mouse embryos were cumulatively labelled with bromodeoxyuridine. Vasoactive intestinal peptide (10(-7)M) shortened S phase and G1 phase of neuroepithelial cells by 50% (4.8-2.4 h) and 58% (1.9-0.8 h), respectively, compared with controls. G2 and M phases were not modified by vasoactive intestinal peptide treatment. Total cell cycle length was consequently reduced by 43% (8.2-4.7 h) in vasoactive intestinal peptide treated embryos, compared with controls. In contrast, vasoactive intestinal peptide did not modify the rate of neuroepithelial cell death as assessed by the proportion of nuclei containing fragmented DNA. These data suggest that vasoactive intestinal peptide stimulates growth in premigratory stages of nervous system development by shortening S and G1 phases of the cell cycle and that S phase duration can be regulated by a physiological peptide.
Collapse
Affiliation(s)
- P Gressens
- Service de Neuropédiatrie and INSERM CRI 97-01, Hôpital Robert-Debré and Faculté Xavier Bichat, Paris, France.
| | | | | | | | | |
Collapse
|
68
|
Gozes I, Bachar M, Bardea A, Davidson A, Rubinraut S, Fridkin M. Protection against developmental deficiencies by a lipophilic VIP analogue. Neurochem Res 1998; 23:689-93. [PMID: 9566607 DOI: 10.1023/a:1022494907001] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Stearyl-Nle-VIP (SNV) is a novel agonist of vasoactive intestinal peptide (VIP) exhibiting a 100-fold greater potency than the parent molecule and specificity for a receptor associated with neuronal survival. Here, the developmental and protective effects of SNV were investigated in vivo using two models of developmental retardation, hypoxia and cholinergic blockade. In both cases chronic administration of SNV during development provided protective effects. Water maze experiments on the weaned animals have demonstrated a prophylactic action for SNV and enhancement of spatial memory in animals exposed to a cholinotoxin. SNV may act by providing neuroprotection, thereby improving cognitive functions. This work is dedicated to Prof. R.J. Wurtman whose inspiration and leadership in the field of neuroscience and cognition is beyond comparison.
Collapse
Affiliation(s)
- I Gozes
- Dept. Clin. Biochem. Sackler Med. Sch. Tel Aviv Univ., Israel.
| | | | | | | | | | | |
Collapse
|
69
|
El-Gehani F, Tena-Sempere M, Huhtaniemi I. Vasoactive intestinal peptide is an important endocrine regulatory factor of fetal rat testicular steroidogenesis. Endocrinology 1998; 139:1474-80. [PMID: 9528923 DOI: 10.1210/endo.139.4.5861] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
This study elaborates our recent preliminary finding that vasoactive intestinal peptide (VIP) has a specific stimulatory effect on fetal rat Leydig cells. We examined the dose-response relationship for the effect of VIP on cAMP and testosterone production by dispersed fetal Leydig cells isolated from rat testes on embryonic day (E) 18.5. Further, we used RT-PCR to examine the expression of the VIP gene in fetal brain and testes and that of the VIP receptor genes in fetal testes and used RIA to measure VIP in testes and plasma during the fetal period. VIP stimulated fetal testicular cAMP production at a dose of 10(-9) mol/liter, whereas a dose as low as 10(-12) mol/liter stimulated testosterone production. This suggests that VIP at low doses may stimulate testosterone production using second messenger pathways other than cAMP. RT-PCR analysis could not reveal either VIP messenger RNA (mRNA) in fetal tissues or VIP1 receptor mRNA in the fetal or newborn testes, whereas VIP2 receptor mRNA was detected in fetal testes as early as E15.5. Northern hybridization analysis showed that the level of expression of VIP2 receptor mRNA is very low in fetal and neonatal testes and increases with age. The testicular VIP content was unmeasurable by our RIA method (i.e. <1 fmol/testis), whereas the circulating level of VIP was 82.9 +/- 1.1 pmol/liter on E17.5 and decreased with advancing fetal age. In conclusion, our results suggest that VIP from an extratesticular source, possibly from the maternal compartment, may regulate fetal testicular steroidogenesis through type 2 receptors as early as E15.5. These findings may be of physiological significance, because the onset of fetal testicular steroidogenesis occurs at an age (E15.5-19.5) before the onset of pituitary LH secretion.
Collapse
Affiliation(s)
- F El-Gehani
- Department of Physiology, University of Turku, Finland
| | | | | |
Collapse
|
70
|
Pellegri G, Magistretti PJ, Martin JL. VIP and PACAP potentiate the action of glutamate on BDNF expression in mouse cortical neurones. Eur J Neurosci 1998; 10:272-80. [PMID: 9753136 DOI: 10.1046/j.1460-9568.1998.00052.x] [Citation(s) in RCA: 81] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
In view of the neurotrophic effect of vasoactive intestinal peptide (VIP), the regulation of brain-derived neurotrophic factor (BDNF) expression by VIP and the related peptide pituitary adenylate cyclase-activating polypeptide (PACAP) was analysed by Northern blot in primary cultures of cortical neurones. Results reported in this article demonstrate that VIP and PACAP stimulate the expression of BDNF mRNA in primary cultures of cortical neurones and astrocytes. In primary cultures of cortical neurones, induction of BDNF mRNA by VIP and PACAP is completely inhibited by the N-methyl-D-aspartate (NMDA) receptor antagonists MK-801 and AP5, therefore indicating that VIP and PACAP do not stimulate BDNF expression directly but rather by potentiating the effect of glutamate tonically released by neurones and acting at NMDA receptors. In addition to its neurotrophic effects, BDNF has been shown to be involved in neuronal plasticity and results reported here suggest that by stimulating BDNF expression, VIP and PACAP could modulate synaptic plasticity in the cerebral cortex.
Collapse
Affiliation(s)
- G Pellegri
- Laboratoire de Recherche Neurologiche, Institut de Physiologie et Service de Neurologie du CHUV, Faculté de Médecine, Université de Lausanne, Switzerland
| | | | | |
Collapse
|
71
|
Ashur-Fabian O, Giladi E, Brenneman DE, Gozes I. Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides. J Mol Neurosci 1997; 9:211-22. [PMID: 9481622 DOI: 10.1007/bf02800503] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Vasoactive intestinal peptide (VIP) has been shown to be a potent promoter of neuronal survival. Pituitary adenylate cyclase-activating peptide (PACAP), a homologous peptide, shares activity and receptor molecules with VIP. The neuroprotective effects of VIP have been shown to be mediated via astroglial-derived molecules. Utilizing a battery of antisense oligodeoxynucleotides directed against the multiple cloned VIP-preferring (VIP receptors 1 and 2) or PACAP-preferring receptors (six splice variants derived from the same gene transcript), the authors have demonstrated the existence of a specific PACAP receptor splice variant (PACAP4 or hop2) on astrocytes as well as a VIP type2 receptor. The identification of the receptors was achieved by incubation of the cells in the presence of the specific antisense oligodeoxynucleotide followed by radiolabeled VIP binding and displacement. Polymerase chain reaction (PCR) coupled to direct sequencing identified the expression of the PACAP4-hop2 receptor splice variant in astrocytes. Neuronal survival assays were conducted in mixed neuronal-glial cultures derived from newborn rat cerebral cortex. When these cultures were exposed to the battery of the antisense oligodeoxynucleotides, in serum-free media, only the PACAP-specific ones (e.g., hop2-specific) had an effect in decreasing neuronal cell counts. Thus, the VIP neuronal survival effect is mediated, at least in part, via a specific PACAP receptor (containing a unique insertion of 27 amino acids--the hop2 cassette). These data indicate that a hop2-like PACAP/VIP receptor is the receptor that mediates neurotropism.
Collapse
Affiliation(s)
- O Ashur-Fabian
- Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Israel
| | | | | | | |
Collapse
|
72
|
Gressens P, Muaku SM, Besse L, Nsegbe E, Gallego J, Delpech B, Gaultier C, Evrard P, Ketelslegers JM, Maiter D. Maternal protein restriction early in rat pregnancy alters brain development in the progeny. BRAIN RESEARCH. DEVELOPMENTAL BRAIN RESEARCH 1997; 103:21-35. [PMID: 9370057 DOI: 10.1016/s0165-3806(97)00109-0] [Citation(s) in RCA: 69] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We assessed the effects of a dietary protein restriction (5% vs. 20% casein in diet) initiated at conception and imposed during the first 2 weeks of rat gestation on postnatal brain development. At the end of the malnutrition period, protein-restricted animals exhibited significantly smaller fetal body weight and brain cortical thickness than controls. At birth and thereafter, body weight was normalized in the progeny. Similarly, brain weight and cytoarchitecture were normal in postnatal animals. In contrast, we observed, during the first 2 postnatal weeks, several abnormalities of brain development which affected all the studied areas for most of the studied parameters: (i) delayed astrocytogenesis as shown by a reduced GFAP staining; (ii) delayed production of hyaluronan in the extracellular matrix studied with binding of biotinylated hyaluronectin; (iii) abnormal neuronal differentiation as shown by reduced expression of MAP-5 and increased expression of MAP-1; (iv) abnormal synaptogenesis as shown by the increased expression of synaptophysin in the basal ganglia; (v) decreased programmed cell death. In adult prenatally protein-restricted animals, all the above parameters were normalized excepted MAP-1 labeling which remained high. In addition, we observed slight alterations of the ventilatory response to hypoxia in adult animals. The present study demonstrates that early protein malnutrition during embryonic development induces multiple, transient alterations of brain development. However, the almost complete normalization in adults of brain architecture and differentiation as well as our physiological data strongly suggest a remarkable plasticity of the developing brain following an early aggression.
Collapse
Affiliation(s)
- P Gressens
- Laboratoire de Neurobiologie et de Physiologie du Développement, INSERM CRI 96-03, Hôpital Robert-Debré, Paris, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
73
|
Vertongen P, De Clerck P, Fournet JC, Martelli H, Hélardot P, Devalck C, Peeters T, Sariban E, Robberecht P. Comparison between vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide levels in neuroblastoma tumour tissues. Neuropeptides 1997; 31:409-13. [PMID: 9413016 DOI: 10.1016/s0143-4179(97)90033-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Vasoactive intestinal polypeptide (VIP) is reported to exert an autocrine control on neuroblastoma cell tumours: VIP is produced by the tumour and stimulates cell differentiation. This study tested the hypothesis that the parent peptide; the pituitary adenylate cyclase activating polypeptide (PACAP) may have a similar role. It was found that PACAP mRNA and PACAP were expressed in 12/12 tumours; it was also observed that PACAP receptor mRNA and functional PACAP receptors were expressed in 12/12 and 5/9 tumours, respectively. VIP mRNA and VIP were detected in 9/12 tumours. VIP receptor mRNA was expressed in 5/12 tumours and functional VIP receptors were never demonstrated. The tumours having the highest VIP levels also had the highest PACAP contents and were associated with a watery diarrhoea syndrome due to activation of intestinal VIP receptors. As PACAP recognizes the PACAP receptors and the VIP receptors with the same high affinity it may contribute to the syndrome and is a likely candidate for an autocrine control of neuroblastoma cell growth and differentiation.
Collapse
Affiliation(s)
- P Vertongen
- Laboratoire de Chimie Biologique et de la Nutrition, Faculté de Médecine, Université Libre de Bruxelles, Belgium
| | | | | | | | | | | | | | | | | |
Collapse
|
74
|
Gozes I, Bachar M, Bardea A, Davidson A, Rubinraut S, Fridkin M, Giladi E. Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease. JOURNAL OF NEUROBIOLOGY 1997; 33:329-42. [PMID: 9298769 DOI: 10.1002/(sici)1097-4695(199709)33:3<329::aid-neu10>3.0.co;2-a] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Stearyl-Nle17-VIP (SNV) is a novel agonist of vasoactive intestinal peptide (VIP) exhibiting a 100-fold greater potency than the parent molecule and specificity for a receptor associated with neuronal survival. Here, mice deficient in apolipoprotein E (ApoE), a molecule associated with the etiology of Alzheimer's disease, served as a model to investigate the developmental and protective effects of SNV. In comparison to control animals, the deficient mice exhibited (a) reduced amounts of VIP messenger RNA; (b) decreased cholinergic activity (c) significant retardation in the acquisition of developmental milestones: forelimb placing behavior and cliff avoidance behavior; and (d) learning and memory impairments. Daily injections of SNV to ApoE-deficient newborn pups resulted in increased cholinergic activity and marked improvements in the time of acquisition of behavioral milestones, with peptide-treated animals developing as fast as control animals and exhibiting improved cognitive functions after cessation of peptide treatment. Specificity was demonstrated in that treatment with a related peptide (PACAP), pituitary adenylate cyclase-activating peptide, produced only limited amelioration. As certain genotypes of ApoE increase the probability of Alzheimer's disease, early counseling and preventive treatments may now offer an important route for therapeutics design.
Collapse
Affiliation(s)
- I Gozes
- Department of Clinical Biochemistry, Sackler Medical School, Tel Aviv University, Israel
| | | | | | | | | | | | | |
Collapse
|
75
|
Gressens P, Marret S, Hill JM, Brenneman DE, Gozes I, Fridkin M, Evrard P. Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J Clin Invest 1997; 100:390-7. [PMID: 9218516 PMCID: PMC508202 DOI: 10.1172/jci119545] [Citation(s) in RCA: 145] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Excitotoxic damage may be a critical factor in the formation of brain lesions associated with cerebral palsy. When injected at birth, the glutamatergic analog ibotenate induces mouse brain lesions that strikingly mimic human microgyria. When ibotenate is injected at postnatal day 5, it produces transcortical necrosis and white matter cysts that mimic human perinatal hypoxic-like lesions. Vasoactive intestinal peptide (VIP) has potent growth-related actions and neuroprotective properties that influence mitosis and neuronal survival in culture. The goal of this study was to assess the protective role of VIP against excitotoxic lesions induced by ibotenate in developing mouse brain. VIP cotreatment reduced ibotenate-induced microgyric-like cortical lesions and white matter cysts by up to 77 and 85%, respectively. VIP protective effects were reproduced by a peptide derived from activity-dependent neurotrophic factor (ADNF), a trophic factor released by VIP-stimulated astrocytes, and by stearyl norleucine VIP, a specific VIP agonist that does not activate adenylate cyclase. Neither forskolin, an adenylate cyclase activator, nor pituitary adenylate cyclase-activating peptide, provided VIP-like protection. VIP and neurotrophic analogs, acting through a cAMP-independent mechanism and inducing ADNF release, could represent new avenues in the understanding and prevention of human cerebral palsy.
Collapse
Affiliation(s)
- P Gressens
- Service de Neuropédiatrie, Hôpital Robert-Debré and Faculté Xavier Bichat, F-75019 Paris, France.
| | | | | | | | | | | | | |
Collapse
|
76
|
Evrard P, Marret S, Gressens P. Environmental and genetic determinants of neural migration and postmigratory survival. ACTA PAEDIATRICA (OSLO, NORWAY : 1992). SUPPLEMENT 1997; 422:20-6. [PMID: 9298787 DOI: 10.1111/j.1651-2227.1997.tb18339.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The study of genetic/epigenetic/environmental factors underlies all therapeutic and preventive approaches in fetal, perinatal and paediatric neurology, including rehabilitation. In this paper, we selected a few targets of environmental determinants of brain development leading to underlying priorities for protection of the developing brain. Preparation of the neural germinative epithelium has to be protected against noxious pharmacological agents. New tools have been developed to improve early neural teratology, including the whole-embryo culture method. The neopallial astrocytic precursors have a dual origin. Astrocytes of the white matter and deep neocortical layers derive from transformed radial glial cells, whereas astrocytes of the upper neocortical layers derive from astrocytic precursors that migrate from the late germinative zone after the end of neuronal migration. Among numerous factors able to interfere with these gliogenetic events are the control factors of the lysosomal and autophagic functions, interfering with radial glial cell transformation into astrocytes. All lesions interrupting the migratory corridors of late astroglial migration can produce cytoarchitectonic disturbances of the neocortical supragranular layers, with long-term consequences. The developing brain is weltering in a complex mixture including newly recognized excitotoxic substances, cytokines and growth factors. These substances are sometimes environmental friends like maternal vasointestinal peptide, which prevents brain intrauterine growth retardation. They are sometimes excellent endogenous friends like neurotrophic excitatory agents in physiological conditions. They become often dangerous killers triggered by environmental signals like hypoxias/ischaemias and toxins produced by intrauterine infections, launching the excitotoxic cascade. In this paper, we reviewed mainly environmental determinants interfering with neural cytogenesis and histogenesis during the embryonic, fetal and neonatal span of early life.
Collapse
Affiliation(s)
- P Evrard
- Laboratoire de Neurologie du Développement, Hôpital Robert Debré, Faculté de Médecine Xavier-Bichat, Université de Paris VII, France
| | | | | |
Collapse
|
77
|
Dibbern DA, Glazner GW, Gozes I, Brenneman DE, Hill JM. Inhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor. J Clin Invest 1997; 99:2837-41. [PMID: 9185505 PMCID: PMC508133 DOI: 10.1172/jci119476] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Intrauterine growth retardation and neurodevelopmental handicaps are common among infants born to HIV-positive mothers and may be due to the actions of virions and/or maternally derived viral products. The viral envelope protein, gp120, is toxic to neurons, induces neuronal dystrophy, and retards behavioral development in neonatal rats. Vasoactive intestinal peptide, a neuropeptide regulator of early postimplantation embryonic growth, and the neuroprotective protein, activity-dependent neurotrophic factor, prevent gp120-induced neurotoxicity. Whole embryo culture of gestational day 9.5 mouse embryos was used to assess the effect of gp120 on growth. Embryos treated with gp120 exhibited a dose-dependent inhibition of growth. gp120-treated embryos (10(-8) M) grew 1.2 somites in the 6-h incubation period, compared with 3.9 somites by control embryos. Embryos treated with gp120 were significantly smaller in cross-sectional area and had significantly less DNA and protein than controls. Growth inhibition induced by gp120 was prevented by cotreatment with vasoactive intestinal peptide or activity-dependent neurotrophic factor. gp120 may play a role in the growth retardation and developmental delays experienced by infants born to HIV-positive mothers. Vasoactive intestinal peptide and related factors may provide a therapeutic strategy in preventing developmental deficits.
Collapse
Affiliation(s)
- D A Dibbern
- Laboratory of Developmental Neurobiology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA
| | | | | | | | | |
Collapse
|
78
|
Gressens P, Paindaveine B, Hill JM, Brenneman DE, Evrard P. Growth factor properties of VIP during early brain development. Whole embryo culture and in vivo studies. Ann N Y Acad Sci 1997; 814:152-60. [PMID: 9160967 DOI: 10.1111/j.1749-6632.1997.tb46153.x] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Vasoactive intestinal peptide (VIP), a 28 amino acid neuropeptide widely distributed in the mammalian nervous system, has potent growth-related actions that influence cell division, neuronal survival, and neurodifferentiation. To address the potential effects of VIP on embryonic growth, whole postimplantation embryo cultures were used. After a 4-hour incubation, VIP stimulated growth as assessed by the following increases from control: embryonic volume (63%), DNA (103%), and protein content (63%), as well as the number of cells in S-phase (490%). No apparent histological abnormalities are produced by VIP. To assess the in vivo function of VIP in early CNS growth, a VIP antagonist (VA) was injected i.p. between E9 and E11. VA induced a dose reduction of the DNA (84% of controls) and protein (80% of controls) contents of the E11 head and a decrease of E17 brain weight (87% of controls). In contrast, body growth was less affected by the antagonist. injections of VA for a longer period (E9 to E17) did not increase the severity of the microcephaly. By ex vivo autoradiography, GTP-sensitive VIP binding sites were detected in the germinative neuroepithelium between E9 and E11, but not between E13 and E15, during neuronal migration. These data demonstrate that VIP regulates mitogenic activity in the premigratory neuroepithelium. Although this effect is limited to a short ontogenic period, blockade of VIP by a specific antagonist induces a severe microcephaly.
Collapse
Affiliation(s)
- P Gressens
- Laboratoire de Neurologie du Développement, Hôpital Robert-Debré, Paris, France.
| | | | | | | | | |
Collapse
|
79
|
Hill JM, Gressens P, Brenneman DE. Growth of the early postimplantation embryo. Regulation by high-affinity, GTP-insensitive VIP receptors. Ann N Y Acad Sci 1997; 814:174-80. [PMID: 9160970 DOI: 10.1111/j.1749-6632.1997.tb46156.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- J M Hill
- Section on Developmental and Molecular Pharmacology, National Institutes of Health, Bethesda, Maryland 20892, USA
| | | | | |
Collapse
|
80
|
Affiliation(s)
- W W Hay
- Department of Pediatrics, University of Colorado School of Medicine, Denver 80262, USA
| | | | | | | |
Collapse
|
81
|
Lu N, DiCicco-Bloom E. Pituitary adenylate cyclase-activating polypeptide is an autocrine inhibitor of mitosis in cultured cortical precursor cells. Proc Natl Acad Sci U S A 1997; 94:3357-62. [PMID: 9096398 PMCID: PMC20374 DOI: 10.1073/pnas.94.7.3357] [Citation(s) in RCA: 158] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/1996] [Accepted: 01/22/1997] [Indexed: 02/04/2023] Open
Abstract
During brain development, an intricate array of signals is likely to control the transition from proliferation to differentiation, particularly in the complex cerebral cortex. Although factors regulating proliferation and differentiation have been identified, little is known about mechanisms governing the exit of precursors from the cell cycle. We now report that pituitary adenylate cyclase-activating polypeptide (PACAP), a new member of the vasoactive intestinal peptide family expressed in embryonic brain, promotes this transition. In virtually pure cultures of embryonic day 13.5 (E13.5) rat cortical precursors, PACAP inhibited [3H]thymidine incorporation by 43%, decreasing the proportion of mitotic cells. Moreover, the peptide promoted morphological and biochemical differentiation; PACAP elicited a 2-fold increase in cells bearing neurites and a 30% increase in neurotrophin trkB receptor expression, indicating that PACAP induced cell cycle withdrawal and promoted neuronal differentiation. The expression of PACAP ligand and receptor in precursors raised the possibility of autocrine function. Indeed, 85% of cells exhibited PACAP immunoreactivity while 64% expressed type I receptor, which, in turn, mediated cAMP activation and phosphorylated cAMP response element binding protein nuclear signaling. Furthermore, treatment with the PACAP antagonist or neutralizing antibody increased DNA synthesis and proliferation, which is consistent with interruption of ongoing mitotic inhibition mediated by endogenous PACAP. Our observations suggest that cortical precursors produce PACAP as an autocrine signal to elicit cell cycle withdrawal, inducing the transition from proliferation to neuronal differentiation.
Collapse
Affiliation(s)
- N Lu
- Department of Neuroscience, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, Piscataway 08854, USA
| | | |
Collapse
|
82
|
Wu JY, Henins KA, Gressens P, Gozes I, Fridkin M, Brenneman DE, Hill JM. Neurobehavioral development of neonatal mice following blockade of VIP during the early embryonic period. Peptides 1997; 18:1131-7. [PMID: 9396053 DOI: 10.1016/s0196-9781(97)00146-0] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Previous work has shown that blockade of VIP function in the early postimplantation embryo results in growth retardation and microcephaly. In the present work, the neurobehavioral development of neonatal mice was examined following treatment of dams with a VIP antagonist during this period. Inhibition of VIP functions during early embryogenesis impaired the performance of 5 of 10 developmental behaviors. These behaviors included developmental milestones (first appearance of ear twitch and eye opening) and complex motor behaviors (negative geotaxis, surface righting, and air righting). The retardation of neurobehavioral development produced by inhibition of VIP action indicates that this peptide is important to the progression of embryonic development.
Collapse
Affiliation(s)
- J Y Wu
- Section on Developmental and Molecular Pharmacology, NICHD, NIH, Bethesda, MD 20892, USA
| | | | | | | | | | | | | |
Collapse
|
83
|
Vertongen P, Schiffmann SN, Gourlet P, Robberecht P. Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Peptides 1997; 18:1547-54. [PMID: 9437715 DOI: 10.1016/s0196-9781(97)00229-5] [Citation(s) in RCA: 74] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Vasoactive Intestinal Polypeptide (VIP) exerts its biological effects through interaction with two high affinity receptors named the VIP1- and the VIP2 receptors. Their messenger RNAs have been mapped in rat brain by in situ hybridization. A cyclic peptide (RO 25-1553) and a secretion analogue ([R16]chicken secretin) were identified as selective agonist peptides for the VIP2- and VIP1 receptors, respectively. The iodinated peptides retained the high affinity and selectivity of the unlabelled peptides and were used for the mapping of each receptor subclass in rat brain. VIP1 receptors were present in the cerebral cortex, the piriform cortex, the claustrum, the caudate-putamen, the dentate gyrus, the lateral amygdaloïd nucleus, the anteroventral thalamic nucleus, the rhomboïd nucleus, the supraoptic nucleus and the choroïd plexus. VIP2 receptors were present in the cerebral cortex, the claustrum, the caudate-putamen, the nucleus accumbens, the lateral septal nuclei, the bed nucleus of the stria terminalis, the basolateral amygdaloïd nucleus, the Ammon's horn, the thalamic nuclei except some centromedial nuclei, the medial habenula, the suprachiasmatic nucleus, the periventricular nucleus, the mammilary nucleus, the superior colliculus and the choroïd plexus.
Collapse
Affiliation(s)
- P Vertongen
- Department of Biochemistry and Nutrition, Faculty of Medicine, Université Libre de Bruxelles, Belgium
| | | | | | | |
Collapse
|
84
|
Gozes I, Lilling G, Davidson A, Bardea A, Reshef A, Glazer R, Zamostiano R, Ashur-Fabian O, Ticher A, Ashkenazi IE, Moody TW, Rubinraut S, Fridkin M, Brenneman DE. Development of VIP agonists and antagonists with tissue and receptor specificity: effects on behavioral maturation, sexual function, and the biologic clock. Ann N Y Acad Sci 1996; 805:159-69; discussion 169-71. [PMID: 8993401 DOI: 10.1111/j.1749-6632.1996.tb17481.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- I Gozes
- Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Israel.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
85
|
Waschek JA. VIP and PACAP receptor-mediated actions on cell proliferation and survival. Ann N Y Acad Sci 1996; 805:290-300; discussion 300-1. [PMID: 8993411 DOI: 10.1111/j.1749-6632.1996.tb17491.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- J A Waschek
- Department of Psychiatry, University of California at Los Angeles 90024-1759, USA.
| |
Collapse
|
86
|
Hill JM, McCune SK, Alvero RJ, Glazner GW, Brenneman DE. VIP regulation of embryonic growth. Ann N Y Acad Sci 1996; 805:259-68; discussion 268-9. [PMID: 8993408 DOI: 10.1111/j.1749-6632.1996.tb17488.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Vasoactive intestinal peptide (VIP) plays a regulatory role in the growth of early postimplantation rodent embryos through its action on receptors localized to the central nervous system (CNS). However, the origin of the VIP influencing embryonic growth is unknown. VIP binding sites have been found prenatally; however, VIP mRNA was not detected in the rat CNS before birth and has been detected in peripheral organs only during the final third of gestation. Recent studies have revealed that VIP receptors were limited to the CNS in the embryonic day 11 (E11) rat embryo/trophoblast, which, in addition, had almost four times the VIP concentration of the E17 fetus. However, neither in situ hybridization or reverse transcriptase-polymerase chain reaction methods detected VIP mRNA in the E11 rat embryo or embryonic membranes. Rat maternal serum revealed a peak in VIP concentration at days E10-E12 of pregnancy, with VIP levels 6- to 10-fold higher than later during pregnancy. Radiolabeled VIP, administered intravenously to pregnant female mice, was found in the E10 embryo. These results suggest that VIP produced by extraembryonic tissues may regulate embryonic growth during the early postimplantation stage of development in the rodent.
Collapse
Affiliation(s)
- J M Hill
- Section on Developmental and Molecular Pharmacology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA.
| | | | | | | | | |
Collapse
|
87
|
Gozes I, Brenneman DE. Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? J Mol Neurosci 1996; 7:235-44. [PMID: 8968945 DOI: 10.1007/bf02737061] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
To understand and intervene in neuronal cell death, intensive investigations have been directed at the discovery of intracellular and extracellular factors that provide natural neuroprotection. This goal has fundamental importance for both rational strategies for the treatment of neurodegenerative diseases and also the delineation of molecular mechanisms that regulate nervous system differentiation and growth. We have discovered a potential interface among these fields of research with activity-dependent neurotrophic factor (ADNF), a protein containing sequence homologies to intracellular stress proteins that is found in the extracellular milieu of astroglial cells incubated with the neuropeptide vasoactive intestinal peptide (VIP). Femtomolar concentrations of ADNF and a short peptide sequence derived from it (a peptidergic active site) protected neurons from death associated with a broad range of toxins, including those related to Alzheimer's disease, the human immunodeficiency virus, excito-toxicity, and electrical blockade. Because the activity of the protein was mimicked by a short peptide fragment, this peptide is now proposed as a lead compound for drug development against neurodegeneration.
Collapse
Affiliation(s)
- I Gozes
- Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Israel
| | | |
Collapse
|
88
|
Lu N, Black IB, DiCicco-Bloom E. A paradigm for distinguishing the roles of mitogenesis and trophism in neuronal precursor proliferation. BRAIN RESEARCH. DEVELOPMENTAL BRAIN RESEARCH 1996; 94:31-6. [PMID: 8816274 DOI: 10.1016/0165-3806(96)00050-8] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
During nervous system development, the generation of neuronal populations is subject to regulation by extracellular growth factors. Traditional views suggest that growth factors promote proliferation by increasing the fraction of precursors that enter the mitotic cycle and subsequently divide (that is, enhance mitosis). However, recent evidence indicates that dividing precursors may undergo cell death. Consequently, a given molecule may also increase neuroblast proliferation by promoting survival of dividing precursors. In the present work, we developed a new approach to distinguish these two distinct effects of growth factors on dividing neuroblasts. By using a brief 6 h culture paradigm of embryonic day 15.5 sympathetic neuroblasts, we minimized cell death, thereby excluding the survival-promoting (trophic) activity of growth factors. In the absence of trophism, measured increases in [3H]thymidine incorporation reflected growth factor mitogenic activity only. Using a well-characterized sympathetic model, we found that insulin, EGF and vasoactive intestinal peptide (VIP) increased [3H]thymidine incorporation 30%, 20% and 46% respectively, consistent with their previously reported mitogenic activity. In contrast, neurotrophin-3 (NT3) and nerve growth factor (NGF), which serve as trophic signals for the neuroblasts, did not elicit any change in [3H]thymidine incorporation, indicating that the neurotrophins are not mitogenic for sympathetic precursors. This approach may be useful in distinguishing mitogenic and trophic regulation of proliferation in other brain precursor populations.
Collapse
Affiliation(s)
- N Lu
- Department of Neuroscience and Cell Biology, UMDNJ/Robert Wood Johnson Medical School, Piscataway 08854, USA
| | | | | |
Collapse
|
89
|
Hill JM, McCune SK, Alvero RJ, Glazner GW, Henins KA, Stanziale SF, Keimowitz JR, Brenneman DE. Maternal vasoactive intestinal peptide and the regulation of embryonic growth in the rodent. J Clin Invest 1996; 97:202-8. [PMID: 8550835 PMCID: PMC507080 DOI: 10.1172/jci118391] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Vasoactive intestinal peptide (VIP) has been shown to regulate early postimplantation growth in rodents through central nervous system receptors. However, the source of VIP mediating these effects is unknown. Although VIP binding sites are present prenatally, VIP mRNA was not detected in the rat central nervous system before birth and was detected in the periphery only during the last third of pregnancy. In the present study, the embryonic day (E11) rat embryo/trophoblast was shown to have four times the VIP concentration of the E17 fetus and to have VIP receptors in the central nervous system. However, no VIP mRNA was detected in the E11 rat embryo or embryonic membranes by in situ hybridization or reverse transcriptase-PCR. RIA of rat maternal serum revealed a peak in VIP concentration at days E10-E12 of pregnancy, with VIP rising to levels 6-10-fold higher than during the final third of pregnancy. After intravenous administration of radiolabeled VIP to pregnant female mice, undegraded VIP was found in the E10 embryo. These results suggest that maternal tissues may provide neuroendocrine support for embryonic growth through a surge of VIP during early postimplantation development in the rodent.
Collapse
Affiliation(s)
- J M Hill
- Section on Developmental and Molecular Pharmacology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA
| | | | | | | | | | | | | | | |
Collapse
|
90
|
Abstract
Chick embryos were treated with single or multiple doses of 0-250 pmol of endothelin-1 (ET-1) or endothelin-3 (ET-3) and their effects on development were examined in embryos ranging from 7 to 14 days in age. The overall sizes of the head, trunk, beak or wings were increased (5-14%) in ET-treated embryos. Additionally, the lengths or widths of the telencephalic or optic lobes and the diencephalon in the embryonic brains were also increased (4-14%). These effects were observed when the embryos were treated with ET for three consecutive days beginning on day 2 of incubation or from day 1-5. Similar results were obtained by a single injection given on the 5th day of incubation, but not on day 1 or 3. Morphological studies suggested that ET-1 and ET-3 promoted maturation rather than non-specific growth in size. Histological studies revealed that ET-treated brain tissues were more cellular and organized in appearance than control brains. There was no increased incidence of vascular abnormalities or structural malformations subsequent to ET-treatment. These results suggest that ET has growth factor-like effects and that treatment on and around the 5th day of incubation seemed to be most effective for the early phase in brain development in chick embryos.
Collapse
Affiliation(s)
- L Hsu
- Department of Biology, Seton Hall University, S. Orange, NJ 07079, USA
| | | |
Collapse
|
91
|
Gozes I, Fridkin M, Brenneman DE. A VIP hybrid antagonist: from developmental neurobiology to clinical applications. Cell Mol Neurobiol 1995; 15:675-87. [PMID: 8719036 DOI: 10.1007/bf02071131] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
1. The 28 amino acid vasoactive intestinal peptide, VIP, was originally isolated from the intestine, following a bioassay measuring vasodilating properties. Immunocytochemistry, receptor binding assays and in situ hybridizations have demonstrated VIP abundance in the nervous system, suggesting multiple bioactivities. 2. A pharmacological approach was chosen to dissect VIP activities and a prototype VIP antagonist (Met-Hybrid) consisting of a carboxyl fragment of VIP7-28 and a six amino acid fragment of neurotensin, neurotensin6-11-VIP7-28 was synthesized. 3. This hybrid peptide was designed to maintain the binding capacity of one parent molecule (VIP), while loosing the agonistic properties, representing a classical competitive receptor antagonist. Furthermore, the new molecule exhibited increased specificity to central nervous system VIP receptors. 4. The Met-Hybrid was originally discovered as a potent inhibitor of VIP function in vivo. In the adult rodent, acute administration of the antagonist resulted in blockade of VIP-mediated potentiation of sexual behavior and chronic intracerebroventricular application impaired VIP-associated learning abilities. During ontogeny, chronic injections of the molecule resulted in neuronal damage, disruption of the diurnal rhythmicity of motor behavior, and retardation in the acquisition of neonatal reflexes in the rat. 5. During gestation, severe microcephaly was induced by acute administration of the Met-Hybrid to pregnant mice. The hybrid antagonist inhibited VIP-stimulated mitosis in whole embryo cultures and in a variety of cancer cell lines in vitro and in vivo, suggesting therapeutical potential.
Collapse
Affiliation(s)
- I Gozes
- Department of Clinical Biochemistry, Tel Aviv University, Israel
| | | | | |
Collapse
|
92
|
Lilling G, Wollman Y, Goldstein MN, Rubinraut S, Fridkin M, Brenneman DE, Gozes I. Inhibition of human neuroblastoma growth by a specific VIP antagonist. J Mol Neurosci 1994; 5:231-9. [PMID: 7577366 DOI: 10.1007/bf02736724] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The 28-amino-acid neuropeptide, vasoactive intestinal peptide (VIP), is a potent mitogen during embryonic development and plays a vital role in brain growth. VIP is also mitogenic for tumor cells, including the human neuroblastoma (NMB). Northern blot analysis has revealed VIP mRNA transcripts in NMB. We now report VIP-like immunoreactivity within these neuroblastoma cells that increased during logarithmic growth and decreased after attaining confluency. About 10(6) seeded cells secreted 5-40 pg of VIP-like immunoreactivity into the medium. These results suggest an autocrine role for VIP in the regulation of neuroblastoma growth. A VIP hybrid antagonist (neurotensin6-11 VIP7-28) that has been shown to inhibit lung cancer proliferation was now tested for inhibition of neuroblastoma growth. Receptor binding studies indicated that the hybrid antagonist displaced [125I]-VIP binding in the neuroblastoma cells (EC50 = 5 x 10(-6)M). Furthermore, as measured by thymidine incorporation and by cell counts, the potent VIP hybrid antagonist inhibited neuroblastoma multiplication in a dose-dependent manner. In conclusion, VIP may be an important regulator of growth of nerve cell progenitors and of tumors derived from neuronal origin and intervening with VIP function may lead to improved treatment of cancer.
Collapse
Affiliation(s)
- G Lilling
- Department of Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Israel
| | | | | | | | | | | | | |
Collapse
|